Individualized Antibiotic Dosage Regimens for Patients with Augmented Renal Clearance

Overview

Journal Front Pharmacol

Date 2023 Aug 11

PMID 37564179

Authors

A-Xi Shi

Qiang Qu

Hai-Hui Zhuang

Xin-Qi Teng

Wei-Xin Xu

Yi-Ping Liu

Yi-Wen Xiao

Jian Qu

Affiliations

Soon will be listed here.

Abstract

Augmented renal clearance (ARC) is a state of enhanced renal function commonly observed in 30%-65% of critically ill patients despite normal serum creatinine levels. Using unadjusted standard dosing regimens of renally eliminated drugs in ARC patients often leads to subtherapeutic concentrations, poor clinical outcomes, and the emergence of multidrug-resistant bacteria. We summarized pharmaceutical, pharmacokinetic, and pharmacodynamic research on the definition, underlying mechanisms, and risk factors of ARC to guide individualized dosing of antibiotics and various strategies for optimizing outcomes. We searched for articles between 2010 and 2022 in the MEDLINE database about ARC patients and antibiotics and further provided individualized antibiotic dosage regimens for patients with ARC. 25 antibiotic dosage regimens for patients with ARC and various strategies for optimization of outcomes, such as extended infusion time, continuous infusion, increased dosage, and combination regimens, were summarized according to previous research. ARC patients, especially critically ill patients, need to make individualized adjustments to antibiotics, including dose, frequency, and method of administration. Further comprehensive research is required to determine ARC staging, expand the range of recommended antibiotics, and establish individualized dosing guidelines for ARC patients.

Citing Articles

Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies.

Eslami M, Safaripour A, Banihashemian S, Nikjoo Niaragh S, Hemmati M, Shojaeian A Microorganisms. 2025; 13(2).

PMID: 40005662 PMC: 11857590. DOI: 10.3390/microorganisms13020295.

From Cure to Crisis: Understanding the Evolution of Antibiotic-Resistant Bacteria in Human Microbiota.

Tahmasebi H, Arjmand N, Monemi M, Babaeizad A, Alibabaei F, Alibabaei N Biomolecules. 2025; 15(1).

PMID: 39858487 PMC: 11764262. DOI: 10.3390/biom15010093.

Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target.

Goyal K, Afzal M, Altamimi A, Babu M, Ballal S, Kaur I Biogerontology. 2024; 26(1):32.

PMID: 39725742 DOI: 10.1007/s10522-024-10173-z.

Dynamic distribution of systemically administered antibiotics in orthopeadically relevant target tissues and settings.

Nielsen M, Jorgensen A, Stilling M, Mikkelsen M, Jorgensen N, Bue M APMIS. 2024; 132(12):992-1025.

PMID: 39530161 PMC: 11582342. DOI: 10.1111/apm.13490.

Suspected poor-quality medicines in Kenya: a retrospective descriptive study of medicine quality-related complaints reports in Kenya's pharmacovigilance database.

Toroitich A, Armitage R, Tanna S BMC Public Health. 2024; 24(1):2561.

PMID: 39300437 PMC: 11414318. DOI: 10.1186/s12889-024-20036-4.

References

Heffernan A, Sime F, Kumta N, Wallis S, McWhinney B, Ungerer J . Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. Antimicrob Agents Chemother. 2022; 66(6):e0218921. PMC: 9211414. DOI: 10.1128/aac.02189-21. View

Wang X, Wang Y, Yao F, Chen S, Hou Y, Zheng Z . Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study. Drug Des Devel Ther. 2021; 15:2129-2141. PMC: 8142937. DOI: 10.2147/DDDT.S303497. View

Udy A, Roberts J, Lipman J . Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011; 7(9):539-43. DOI: 10.1038/nrneph.2011.92. View

Gijsen M, Huang C, Flechet M, Van Daele R, Declercq P, Debaveye Y . Development and External Validation of an Online Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically Ill Patients: The Augmented Renal Clearance Predictor. Crit Care Med. 2020; 48(12):e1260-e1268. DOI: 10.1097/CCM.0000000000004667. View

Irving P, Gecse K . Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Gastroenterology. 2022; 162(5):1512-1524. DOI: 10.1053/j.gastro.2022.02.014. View

Campassi M, Gonzalez M, Masevicius F, Risso Vazquez A, Moseinco M, Navarro N . [Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment]. Rev Bras Ter Intensiva. 2014; 26(1):13-20. PMC: 4031886. DOI: 10.5935/0103-507x.20140003. View

Fu W . Clinical and laboratory studies of a new cephalosporin derivative--cefathiamidine. Chin Med J (Engl). 1979; 92(1):26-36. View

Monk J, Price A, Benfield P, Todd P, Ward A . Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988; 35(4):373-447. DOI: 10.2165/00003495-198835040-00003. View

Fournier A, Goutelle S, Que Y, Eggimann P, Pantet O, Sadeghipour F . Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125536. DOI: 10.1128/AAC.00505-18. View

10.

Huang G, Qiu Y, Liu T, Lu J . Comparison of Vancomycin Clearance Between Augmented Renal Clearance and Normal Renal Function in Critically Ill Infants: A Population Pharmacokinetics Study. J Clin Pharmacol. 2022; 62(7):863-872. DOI: 10.1002/jcph.2029. View

11.

Gregoire N, Marchand S, Ferrandiere M, Lasocki S, Seguin P, Vourch M . Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother. 2018; 74(1):117-125. DOI: 10.1093/jac/dky374. View

12.

Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I . Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017; 72(10):2891-2897. DOI: 10.1093/jac/dkx209. View

13.

Ito A, Kohira N, Bouchillon S, West J, Rittenhouse S, Sader H . In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2015; 71(3):670-7. DOI: 10.1093/jac/dkv402. View

14.

Kim A, Kuti J, Nicolau D . Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2010; 31(11):2765-78. DOI: 10.1016/j.clinthera.2009.11.026. View

15.

Beranger A, Benaboud S, Urien S, Moulin F, Bille E, Lesage F . Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance. Clin Pharmacokinet. 2018; 58(2):223-233. DOI: 10.1007/s40262-018-0682-1. View

16.

Bryson H, Brogden R . Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1994; 47(3):506-35. DOI: 10.2165/00003495-199447030-00008. View

17.

Kim Y, Lee D, Jeon J, Jang H, Kim H, Jin K . Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections. Clin Ther. 2018; 40(8):1384-1395. DOI: 10.1016/j.clinthera.2018.07.001. View

18.

Michalopoulos A, Karatza D . Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther. 2010; 8(9):1009-17. DOI: 10.1586/eri.10.88. View

19.

El-Haffaf I, Caissy J, Marsot A . Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2021; 60(7):855-875. DOI: 10.1007/s40262-021-01013-1. View

20.

Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M . Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care. 2008; 36(5):674-80. DOI: 10.1177/0310057X0803600507. View